Cardiff Oncology, Inc. Cash Flow Statement
CRDF|14 years of annual SEC 10-K data (FY2012-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 14 fiscal years. All figures from audited SEC 10-K filings.
Cardiff Oncology, Inc. used $38M in operating cash flow and negative free cash flow of $38M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$45.9M | -$41.4M | -$38.7M | -$28.3M | -$19.3M | -$19.3M | -$16.4M | -$24.9M | -$39.2M | -$14.3M | -$27.5M | -$14.3M | -$14.8K | -$14.8K |
| Depreciation & Amortization | $364.0K | $398.0K | $236.0K | $451.0K | $466.0K | $466.0K | $494.2K | $1.2M | $1.1M | $234.8K | $378.7K | $234.8K | $10.3K | $10.3K |
| Operating Cash Flow | -$37.9M | -$30.9M | -$33.8M | -$23.0M | -$16.3M | -$16.3M | -$13.3M | -$23.3M | -$31.0M | -$12.7M | -$22.1M | -$12.7M | -$1.9M | -$1.9M |
| Capital Expenditures | $44.0K | $582.0K | $1.0M | $205.0K | $211.0K | $211.0K | $67.6K | $101.1K | $823.5K | $363.3K | $2.2M | $363.3K | $1.5K | $1.5K |
| Free Cash Flow | -$38.0M | -$31.5M | -$34.8M | -$23.2M | -$16.5M | -$16.5M | -$13.3M | -$23.4M | -$31.9M | -$13.1M | -$24.4M | -$13.1M | -$1.9M | -$1.9M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | $500.0K | $500.0K |
| FCF Margin | -6402.5% | -6448.6% | -9022.3% | -6474.9% | -4515.3% | -4515.4% | -5451.1% | -4626.4% | -8361.5% | -4672.3% | -7787.4% | -4672.3% | -749.6% | -749.6% |